Cognition Therapeutics CEO to Showcase Innovations at Key Conferences

Cognition Therapeutics CEO Highlights Innovations in Neurological Research

PURCHASE, N.Y. – Cognition Therapeutics, Inc. (NASDAQ: CGTX), recognized for its groundbreaking work on treatments for neurodegenerative disorders, has announced plans for CEO Lisa Ricciardi to engage in a series of important conferences coinciding with the prominent JP Morgan Healthcare Conference.

Upcoming Conference Participation

Ms. Ricciardi expressed her enthusiasm about these platforms, stating, "I am eager to share the remarkable advancements we achieved in our Alzheimer’s and dementia with Lewy body programs throughout the past year." These advancements culminated in a successful SHIMMER study, which yielded encouraging topline results for patients dealing with dementia with Lewy bodies. Ms. Ricciardi is set to present these findings during the upcoming International Lewy Body Dementia Conference scheduled for the end of January.

Longwood Healthcare Leaders Stanford Summit

The conference will take place on January 11, where Ms. Ricciardi will partake in a panel discussion focused on accelerating drug development. The event is housed at the luxurious Four Seasons in San Francisco, CA.

Sachs 8th Annual Neuroscience Innovation Forum

On January 12, she will participate in the Sachs 8th Annual Neuroscience Innovation Forum, contributing to a vital discussion around innovation in Alzheimer’s and related cognitive disorders. The presentation is scheduled for 1:40 PM in Track C at the Marines’ Memorial Club, also in San Francisco.

Significant Developments at Cognition Therapeutics

In addition to presenting at these conferences, Cognition Therapeutics is on the brink of a major regulatory milestone. The team is preparing for an end-of-Phase 2 meeting with the FDA concerning results from their SHINE study, which focuses on mild-to-moderate Alzheimer’s disease. This regulatory dialogue is critical as they navigate the intricate pathways of drug approval and development.

Cognition has also achieved an important milestone with the clearance of the generic name for its leading candidate, previously known as CT1812, which will be officially referred to as zervimesine. This development highlights the company’s commitment to transparency and the progressive evolution of its therapeutic pipeline.

About Cognition Therapeutics

Cognition Therapeutics, Inc. is at the forefront of biopharmaceutical innovation aimed at addressing age-related degenerative disorders affecting the central nervous system and retina. The company’s research focuses on small molecule therapeutics that target these conditions, including cognitive impairments associated with Alzheimer’s disease and dementia with Lewy bodies.

The ongoing clinical trials for zervimesine underline the company’s strategic focus on pathways that are integral to brain health. Highlighting its innovative pipeline of ?-2 receptor modulators, Cognition believes these therapies can offer distinct advantages over existing treatment methodologies. For additional information about Cognition Therapeutics and their evolving clinical programs, please visit www.cogrx.com.

Frequently Asked Questions

What recent advancements has Cognition Therapeutics achieved?

Cognition Therapeutics recently reported positive topline results from their Phase 2 SHIMMER study focusing on dementia with Lewy bodies, and they are set to present these findings soon.

What is zervimesine?

Zervimesine, previously known as CT1812, is a promising drug candidate currently under investigation for the treatment of Alzheimer’s disease and related cognitive disorders.

When are the scheduled conferences where Lisa Ricciardi will speak?

Lisa Ricciardi will speak at the Longwood Healthcare Leaders Stanford Summit on January 11 and the Sachs 8th Annual Neuroscience Innovation Forum on January 12.

What is the significance of the FDA meeting for Cognition Therapeutics?

The upcoming FDA meeting represents a critical step for Cognition as they discuss results from their SHINE study, which plays a vital role in advancing their Alzheimer's drug development.

How can I learn more about Cognition Therapeutics?

More information about Cognition Therapeutics and its innovative therapies can be found on their official website at www.cogrx.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.